Association between Metformin Use and Survival in Nonmetastatic Rectal Cancer Treated with a Curative Resection: A Nationwide Population Study
2
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Purpose Metformin is associated with an anticancer effect. However, the effects of metformin in rectal cancer are controversial. This study investigated the impact of metformin on the survival of patients with diabetes mellitus and nonmetastatic rectal cancer who underwent curative surgery. Materials and Methods The database was provided by the Korea Center Cancer Registry and National Health Insurance Service of the Republic of Korea. A cohort of patients with newly diagnosed rectal cancer between 2005 and 2011 was identified. Drug exposure was defined as receiving the oral hypoglycemic agent for at least 90 days over the period from 6 months before the initial diagnosis of rectal cancer to the last follow-up. Results A total of 4,503 patients were prescribed oral hypoglycemic agents and classified as the diabetic group, of which 3,694 patients received metformin for at least 90 days. Unadjusted analyses showed a significantly higher overall survival (hazard ratio, 0.596; 95% confidence interval, 0.506 to 0.702) and rectal cancer-specific survival (hazard ratio, 0.621; 95% confidence interval, 0.507 to 0.760) in the metformin group than in the nonmetformin group. The adjusted overall survival (hazard ratio, 0.631; 95% confidence interval, 0.527 to 0.755) and cancer-specific survival (hazard ratio, 0.598; 95% confidence interval, 0.479 to 0.746) in the group with a medication possession ratio of 80% or greater was significantly higher than in the group with a medication possession ratio of less than 80%. Conclusion Metformin use is associated with overall and cancer-specific survival in diabetic patients with a nonmetastatic rectal cancer treated with a curative resection.
Abstract
Purpose Metformin is associated with an anticancer effect. However, the effects of metformin in rectal cancer are controversial. This study investigated the impact of metformin on the survival of patients with diabetes mellitus and nonmetastatic rectal cancer who underwent curative surgery. Materials and Methods The database was provided by the Korea Center Cancer Registry and National Health Insurance Service of the Republic of Korea. A cohort of patients with newly diagnosed rectal cancer between 2005 and 2011 was identified. Drug exposure was defined as receiving the oral hypoglycemic agent for at least 90 days over the period from 6 months before the initial diagnosis of rectal cancer to the last follow-up. Results A total of 4,503 patients were prescribed oral hypoglycemic agents and classified as the diabetic group, of which 3,694 patients received metformin for at least 90 days. Unadjusted analyses showed a significantly higher overall survival (hazard ratio, 0.596; 95% confidence interval, 0.506 to 0.702) and rectal cancer-specific survival (hazard ratio, 0.621; 95% confidence interval, 0.507 to 0.760) in the metformin group than in the nonmetformin group. The adjusted overall survival (hazard ratio, 0.631; 95% confidence interval, 0.527 to 0.755) and cancer-specific survival (hazard ratio, 0.598; 95% confidence interval, 0.479 to 0.746) in the group with a medication possession ratio of 80% or greater was significantly higher than in the group with a medication possession ratio of less than 80%. Conclusion Metformin use is associated with overall and cancer-specific survival in diabetic patients with a nonmetastatic rectal cancer treated with a curative resection.
참고문헌 (30)
- 정규원, "Cancer Statistics in Korea: Incidence, Mortality, Survival, and Prevalence in 2012", Cancer Research and Treatment, 47(2), pp.127~141 (2015), 대한암학회[DOI]
- International Agency for Research on Cancer, "Globocan 2013: cancer fact sheets for colorectal cancer" (2013), International Agency for Research on Cancer
- Edge SB, "AJCC cancer staging manual" (2010), Springer-Verlag
- Larsson SC, "Diabetes mellitus and risk of breast cancer : a meta-analysis", Int J Cancer, 121, pp.856~862 (2007)
- Friberg E, "Diabetes mellitus and risk of endometrial cancer : a meta-analysis", Diabetologia, 50, pp.1365~1374 (2007)
- Coughlin SS, "Diabetes mellitus as a predictor of cancer mortality in a large cohort of US adults", Am J Epidemiol, 159, pp.1160~1167 (2004)
- Siddiqui AA, "Elevated HbA1c is an independent predictor of aggressive clinical behavior in patients with colorectal cancer : a case-control study", Dig Dis Sci, 53, pp.2486~2494 (2008)
- van Staa TP, "Glucoselowering agents and the patterns of risk for cancer : a study with the General Practice Research Database and secondary care data", Diabetologia, 55, pp.654~665 (2012)
- Chowdhury TA, "Diabetes and cancer", QJM, 103, pp.905~915 (2010)
- Geraldine N, "Relation between diabetes, metformin treatment and the occurrence of malignancies in a Belgian primary care setting", Diabetes Res Clin Pract, 97, pp.331~336 (2012)
- Decensi A, "Metformin and cancer risk in diabetic patients : a systematic review and meta-analysis", Cancer Prev Res(Phila), 3, pp.1451~1461 (2010)
- Noto H., "Cancer risk in diabetic patients treated with metformin: a systematic review and meta-analysis", PLoS One, 7(3), pp.e33411~ (2012)
- Dowling RJ, "Metformin inhibits mammalian target of rapamycin-dependent translation initiation in breast cancer cells", Cancer Res, 67, pp.10804~10812 (2007)
- Cardel M, "Long-term use of metformin and colorectal cancer risk in type II diabetics : a population-based case-control study", Cancer Med, 3, pp.1458~1466 (2014)
- Lee JH, "The effects of metformin on the survival of colorectal cancer patients with diabetes mellitus", Int J Cancer, 131, pp.752~759 (2012)
- Cossor FI, "Diabetes, metformin use, and colorectal cancer survival in postmenopausal women", Cancer Epidemiol, 37, pp.742~749 (2013)
- National Comprehensive Cancer Network, "NCCN guidelines for treatment of cancer by site: rectal cancer. v2" (2015), National Comprehensive Cancer Network
- Skinner HD, "Metformin use and improved response to therapy in rectal cancer", Cancer Med, 2, pp.99~107 (2013)
- National Comprehensive Cancer Network, "NCCN guidelines for treatment of cancer by site: colon cancer, ver. 2" (2015), National Comprehensive Cancer Network
- Lee YC, "Differences in survival between colon and rectal cancer from SEER data", PLoS One, 8, pp.e78709~ (2013)
- Charlson ME, "A new method of classifying prognostic comorbidity in longitudinal studies : development and validation", J Chronic Dis, 40, pp.373~383 (1987)
- Gross CP, "Multimorbidity and survival in older persons with colorectal cancer", J Am Geriatr Soc, 54, pp.1898~1904 (2006)
- Polednak AP, "Comorbid diabetes mellitus and risk of death after diagnosis of colorectal cancer : a population-based study", Cancer Detect Prev, 30, pp.466~472 (2006)
- Luo W, "Diabetes mellitus and the incidence and mortality of colorectal cancer : a meta-analysis of 24cohort studies", Colorectal Dis, 14, pp.1307~1312 (2012)
- Stein KB, "Colorectal cancer outcomes, recurrence, and complications in persons with and without diabetes mellitus : a systematic review and meta-analysis", Dig Dis Sci, 55, pp.1839~1851 (2010)
- Jiang Y, "Diabetes mellitus and incidence and mortality of colorectal cancer : a systematic review and meta-analysis of cohort studies", Eur J Epidemiol, 26, pp.863~876 (2011)
- Caudle AS, "Diabetes mellitus affects response to neoadjuvant chemoradiotherapy in the management of rectal cancer", Ann Surg Oncol, 15, pp.1931~1936 (2008)
- Garrett CR, "Survival advantage observed with the use of metformin in patients with type II diabetes and colorectal cancer", Br J Cancer, 106, pp.1374~1378 (2012)
- Mei ZB, "Survival benefits of metformin for colorectal cancer patients with diabetes: a systematic review and meta-analysis", PLoS One, 9, pp.e91818~ (2014)
- Spillane S, "A cohort study of metformin exposure and survival in patients with stage I-III colorectal cancer", Cancer Epidemiol Biomarkers Prev, 22, pp.1364~1373 (2013)